-
公开(公告)号：US20070037170A1
公开(公告)日：2007-02-15
申请号：US11201282
申请日：2005-08-11
申请人： Israel Nur , Liliana Bar , Orgad Laub
发明人： Israel Nur , Liliana Bar , Orgad Laub
CPC分类号： C07K16/081 , A61K38/00 , A61K39/39591 , A61K2039/505 , C07K2319/00
摘要： A method for preparing a concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, comprising: (a) selecting a population of individuals previously vaccinated against one or more antigens associated with the pathogenic microorganism; (b) determining the level of specific antibodies immunoreactive with the pathogenic microorganism in a blood or blood component of the individuals to identify very high titre individuals having a very high titre of the specific antibodies; (c) combining blood or blood components comprising immunoglobulins from the very high titre individuals; and (d) purifying and/or concentrating the product of step (c), thereby obtaining a concentrated immunoglobulin composition. Also disclosed is a concentrated immunoglobulin composition comprising specific antibodies immunoreactive with a pathogenic microorganism, characterized in that the titre of specific antibodies of the composition is at least 5 times higher than the average titre of specific antibodies of a population of individuals previously vaccinated against one or more antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates, and is therefore suitable for both iv and im administration. In a preferred embodiment, the pathogenic microorganism is smallpox virus or vaccinia virus.
摘要翻译： 一种制备用于治疗接种疫苗或感染病原微生物的受试者的浓缩免疫球蛋白组合物的方法，包括：（a）选择先前针对与病原微生物相关的一种或多种抗原接种的个体群体; （b）确定在个体的血液或血液成分中与病原微生物免疫反应的特异性抗体的水平，以鉴定具有非常高的特异性抗体滴度的极高滴度的个体; （c）从非常高的滴度个体组合包含免疫球蛋白的血液或血液成分; 和（d）纯化和/或浓缩步骤（c）的产物，由此获得浓缩的免疫球蛋白组合物。 还公开了包含与病原微生物免疫反应性的特异性抗体的浓缩免疫球蛋白组合物，其特征在于组合物的特异性抗体滴度比先前接种于一种或多种疫苗的个体群体的特异性抗体的平均滴度高至少5倍 更多与病原微生物相关的抗原。 该组合物具有相对高的蛋白质浓度和低百分比的蛋白质聚集体，因此适用于iv和im施用。 在优选的实施方案中，致病微生物是天花病毒或痘苗病毒。
-
公开(公告)号：US09365635B2
公开(公告)日：2016-06-14
申请号：US13619011
申请日：2012-09-14
申请人： Israel Nur , Liliana Bar , Orgad Laub
发明人： Israel Nur , Liliana Bar , Orgad Laub
IPC分类号： A61K38/00 , C07K16/08 , A61K39/395 , A61K39/00
CPC分类号： C07K16/081 , A61K38/00 , A61K39/39591 , A61K2039/505 , C07K2319/00
摘要： A concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, is made by (a) selecting a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism; (b) identifying very high titer individuals by determining the level of specific antibodies immunoreactive with the pathogenic microorganism in the blood of the individuals; (c) combining blood from the very high titer individuals; and (d) purifying and/or concentrating the product of step (c). A concentrated immunoglobulin composition can include specific antibodies immunoreactive with a pathogenic microorganism, wherein the titer of specific antibodies is at least 5 times higher than the average titer of specific antibodies of a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates. The pathogenic microorganism is preferably smallpox virus or vaccinia virus.
摘要翻译： 用于治疗接种疫苗或感染致病微生物的受试者的浓缩的免疫球蛋白组合物是通过（a）选择先前针对与病原微生物相关的抗原进行接种的个体群体; （b）通过确定与个体血液中的病原微生物免疫反应的特异性抗体的水平来鉴定非常高的滴度个体; （c）结合来自极高滴度个体的血液; 和（d）纯化和/或浓缩步骤（c）的产物。 浓缩的免疫球蛋白组合物可以包括与病原微生物免疫反应的特异性抗体，其中特异性抗体的滴度比先前接种抗原与病原微生物相关抗原的个体群体的特异性抗体的平均滴度高至少5倍。 该组合物具有相对高的蛋白质浓度和低百分比的蛋白质聚集体。 病原微生物优选为天花病毒或痘苗病毒。
-
公开(公告)号：US20130011388A1
公开(公告)日：2013-01-10
申请号：US13619011
申请日：2012-09-14
申请人： Israel Nur , Liliana Bar , Orgad Laub
发明人： Israel Nur , Liliana Bar , Orgad Laub
IPC分类号： A61K39/395 , C07K16/08 , A61P31/20 , C07K16/00
CPC分类号： C07K16/081 , A61K38/00 , A61K39/39591 , A61K2039/505 , C07K2319/00
摘要： A concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, is made by (a) selecting a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism; (b) identifying very high titre individuals by determining the level of specific antibodies immunoreactive with the pathogenic microorganism in the blood of the individuals; (c) combining blood from the very high titre individuals; and (d) purifying and/or concentrating the product of step (c). A concentrated immunoglobulin composition can include specific antibodies immunoreactive with a pathogenic microorganism, wherein the titre of specific antibodies is at least 5 times higher than the average titre of specific antibodies of a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates. The pathogenic microorganism is preferably smallpox virus or vaccinia virus.
摘要翻译： 用于治疗接种疫苗或感染致病微生物的受试者的浓缩的免疫球蛋白组合物是通过（a）选择先前针对与病原微生物相关的抗原进行接种的个体群体; （b）通过确定与个体血液中的病原微生物免疫反应的特异性抗体的水平来鉴定非常高的滴度个体; （c）结合极高滴度个体的血液; 和（d）纯化和/或浓缩步骤（c）的产物。 浓缩的免疫球蛋白组合物可以包括与病原微生物免疫反应的特异性抗体，其中特异性抗体的滴度比先前接种抗原与病原微生物相关抗原的个体群体的特异性抗体的平均滴度高至少5倍。 该组合物具有相对高的蛋白质浓度和低百分比的蛋白质聚集体。 病原微生物优选为天花病毒或痘苗病毒。
-
公开(公告)号：US08354249B2
公开(公告)日：2013-01-15
申请号：US11201282
申请日：2005-08-11
申请人： Israel Nur , Liliana Bar , Orgad Laub
发明人： Israel Nur , Liliana Bar , Orgad Laub
IPC分类号： C12P21/04
CPC分类号： C07K16/081 , A61K38/00 , A61K39/39591 , A61K2039/505 , C07K2319/00
摘要： A method for preparing a concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, comprising: (a) selecting a population of individuals previously vaccinated against one or more antigens associated with the pathogenic microorganism; (b) determining the level of specific antibodies immunoreactive with the pathogenic microorganism in a blood or blood component of the individuals to identify very high titre individuals having a very high titre of the specific antibodies; (c) combining blood or blood components comprising immunoglobulins from the very high titre individuals; and (d) purifying and/or concentrating the product of step (c), thereby obtaining a concentrated immunoglobulin composition. Also disclosed is a concentrated immunoglobulin composition comprising specific antibodies immunoreactive with a pathogenic microorganism, characterized in that the titre of specific antibodies of the composition is at least 5 times higher than the average titre of specific antibodies of a population of individuals previously vaccinated against one or more antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates, and is therefore suitable for both iv and im administration. In a preferred embodiment, the pathogenic microorganism is smallpox virus or vaccinia virus.
摘要翻译： 一种制备用于治疗接种疫苗或感染病原微生物的受试者的浓缩免疫球蛋白组合物的方法，包括：（a）选择先前针对与病原微生物相关的一种或多种抗原接种的个体群体; （b）确定在个体的血液或血液成分中与病原微生物免疫反应的特异性抗体的水平，以鉴定具有非常高的特异性抗体滴度的极高滴度的个体; （c）从非常高的滴度个体组合包含免疫球蛋白的血液或血液成分; 和（d）纯化和/或浓缩步骤（c）的产物，由此获得浓缩的免疫球蛋白组合物。 还公开了包含与病原微生物免疫反应性的特异性抗体的浓缩免疫球蛋白组合物，其特征在于组合物的特异性抗体滴度比先前接种于一种或多种疫苗的个体群体的特异性抗体的平均滴度高至少5倍 更多与病原微生物相关的抗原。 该组合物具有相对高的蛋白质浓度和低百分比的蛋白质聚集体，因此适用于iv和im施用。 在优选的实施方案中，致病微生物是天花病毒或痘苗病毒。
-
5.发明授权公开(公告)号：US08981058B2
公开(公告)日：2015-03-17
申请号：US13847898
申请日：2013-03-20
申请人： Israel Nur , Liliana Bar , Guy Tomer , Eyal Sheetrit
发明人： Israel Nur , Liliana Bar , Guy Tomer , Eyal Sheetrit
CPC分类号： A61L15/425 , A61K9/70 , A61K38/4833 , A61L15/32 , A61L15/325 , A61L15/44 , A61L2300/252 , A61L2300/418 , A61L2300/606 , A61L2400/04
摘要： The present invention is directed to a method for manufacturing a cross-linked gelatin sponge having a surface by providing a cross-linked gelatin sponge, wetting the surface of the sponge by applying a sufficient amount of liquid comprising a protein or peptide active ingredient, wherein a sufficient amount of liquid is one that retains the flexibility of the sponge even after drying. The sponge is then dried the sponge to obtain a flexible, dry and ready to use cross linked gelatin sponge having a layer of protein or peptide active ingredient on the surface thereof.
摘要翻译： 本发明涉及通过提供交联明胶海绵来制造具有表面的交联明胶海绵的方法，通过施加足量的包含蛋白质或肽活性成分的液体来润湿海绵的表面，其中 足够量的液体即使在干燥后也保持海绵的柔韧性。 然后将海绵干燥成海绵，以获得在其表面上具有蛋白质或肽活性成分层的柔性，干燥且准备使用的交联明胶海绵。
-
6.发明授权公开(公告)号：US08968724B2
公开(公告)日：2015-03-03
申请号：US12675234
申请日：2008-08-29
申请人： Edna Bechor , Liliana Bar , Israel Nur
发明人： Edna Bechor , Liliana Bar , Israel Nur
CPC分类号： A61K35/16 , A61K35/545 , A61K38/1709 , A61K38/363 , A61L27/3616 , A61L27/3804 , A61L27/3856 , A61L27/3878 , A61L2430/38 , C12N5/0655 , C12N2500/84 , A61K2300/00
摘要： The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronectin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration.
摘要翻译： 本发明涉及包含适当的纤连蛋白/纤维蛋白原比例的病毒灭活血浆冷沉淀物浓缩物（VIPCC）用于治疗脊椎疾病，病症或病症如椎间盘退变的用途。
-
公开(公告)号：US08563288B2
公开(公告)日：2013-10-22
申请号：US12289499
申请日：2008-10-29
申请人： Israel Nur , Liliana Bar , Malkit Azachi
发明人： Israel Nur , Liliana Bar , Malkit Azachi
CPC分类号： C12N9/6435 , C07K1/22 , C12Y304/21007
摘要： A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6-8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.
摘要翻译： 一种通过使混合物与刚性氨基酸接触的方法，其特征在于从含有纤维蛋白溶酶（ogen）或纤溶酶的混合物中除去或分离纤维蛋白原（纤维蛋白原）存在下的纤维蛋白溶酶或纤溶酶，其中氨基酸和羧基的氨基 氨基酸约6-8埃，优选约7埃，刚性氨基酸通过氨基酸的氨基与载体共价结合。
-
8.发明申请公开(公告)号：US20110045034A1
公开(公告)日：2011-02-24
申请号：US12920000
申请日：2009-03-02
申请人： Israel Nur , Eyal Sheetrit , Liliana Bar , Guy Tomer
发明人： Israel Nur , Eyal Sheetrit , Liliana Bar , Guy Tomer
CPC分类号： A61L15/425 , A61K9/70 , A61K38/4833 , A61L15/32 , A61L15/325 , A61L15/44 , A61L2300/252 , A61L2300/418 , A61L2300/606 , A61L2400/04
摘要： The invention relates to an improved dry cross-linked gelatin sponge comprising a layer of an active ingredient, to methods of its preparation and uses thereof.
摘要翻译： 本发明涉及包含活性成分层的改进的干交联明胶海绵，其制备方法及其用途。
-
公开(公告)号：US20100217231A1
公开(公告)日：2010-08-26
申请号：US12708453
申请日：2010-02-18
申请人： Erez Ilan , Moti Meron , Kfir Regev , Liliana Bar , Israel Nur
发明人： Erez Ilan , Moti Meron , Kfir Regev , Liliana Bar , Israel Nur
CPC分类号： A61M5/1582 , A61B17/00491 , A61B2017/00495 , A61M5/3297 , A61M2025/0039
摘要： The device for administering an at least two-component substance comprises a concentric lumen arrangement including (i) an inner cannula having a lumen with an inlet opening at a first end and a tip with an outlet opening at a second end opposite its first end, and (ii) an outer sheath having opposite first and second ends facing the respective first and second ends of the inner cannula, and surrounding the inner cannula along an axial length between the first and second ends of the inner cannula, wherein the outer sheath at its second end is sealingly and fixedly connected to the inner cannula and defining an outer lumen around the inner cannula, and wherein the inner cannula is provided with at least one opening for providing fluid communication between the outer lumen around the inner cannula and the lumen of the inner cannula.
摘要翻译： 用于施用至少两种组分物质的装置包括同心的腔排列，其包括（i）具有在第一端具有入口开口的内腔和在其第一端相对的第二端处具有出口开口的末端的内套管， 和（ii）外护套，其具有相对的第一和第二端面向所述内套管的相应的第一和第二端，并且沿着所述内套管的第一和第二端之间的轴向长度包围所述内套管，其中， 其第二端密封地和固定地连接到内套管并且围绕内插管限定外腔，并且其中内插管设置有至少一个开口，用于提供围绕内插管的外腔与内套管之间的流体连通 内套管。
-
公开(公告)号：US20090176293A1
公开(公告)日：2009-07-09
申请号：US12289499
申请日：2008-10-29
申请人： Israel Nur , Liliana Bar , Malkit Azachi
发明人： Israel Nur , Liliana Bar , Malkit Azachi
IPC分类号： C12N9/68
CPC分类号： C12N9/6435 , C07K1/22 , C12Y304/21007
摘要： A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6-8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.
摘要翻译： 一种通过使混合物与刚性氨基酸接触的方法，其特征在于从含有纤维蛋白溶酶（ogen）或纤溶酶的混合物中除去或分离纤维蛋白原（纤维蛋白原）存在下的纤维蛋白溶酶或纤溶酶，其中氨基酸和羧基的氨基 氨基酸约6-8埃，优选约7埃，刚性氨基酸通过氨基酸的氨基与载体共价结合。
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.034 秒)
